Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2

Journal of Medical Genetics

Volumn 44, Issue 1, 2007, Pages 1-9

  Alter, Blanche P ^a   Rosenberg, Philip S ^a   Brody, Lawrence C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BIRTH DEFECT; BRAIN TUMOR; BREAST CANCER; CANCER RISK; CLINICAL FEATURE; DISEASE SEVERITY; DNA POLYMORPHISM; FANCONI ANEMIA; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HUMAN; LEUKEMIA; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ADULT; ALLELES; BRCA2 PROTEIN; CHILD, PRESCHOOL; FAMILY; FANCONI ANEMIA; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MALE; MUTATION; NEOPLASMS; PHENOTYPE;

EID: 33846415079     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.043257     Document Type: Review

References (37)

1. Alter BP. Inherited bone marrow failure syndromes. In: Nathan DG, Orkin SH, Look AT, Ginsburg D, eds. Nathan and Oski's Hematology of Infancy and Childhood, 6th edn. Philadelphia, PA: WB Saunders, 2003:280-305.
2. Taniguchi T, D'Andrea AD. The molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006;107:4223-33.
3. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005;19:2925-40.
4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
5. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-16.
6. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249-62.
7. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
8. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, Arwert F, Mathew CG, Zdzienicka MZ, Hiom K, de Winter JP, Joenje H. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005;37:934-5.
9. Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P, Batish SD, Kalb R, Velleuer E, Barral S, Ott J, Petrini J, Schindler D, Hanenberg H, Auerbach AD. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005;37:931-3.
10. Online Mendelian Onheritance in Man (OMIM). http://www.ncbi.nlm. nih.gov/Omim/
11. Sharan SK, Morimatsu M, Albrecht U, Lim D-S, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1997;386:804-10.
12. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997;11:226-41.
13. Szabo C, Masiello A, Ryan JF, Brody LC. The breast cancer information core: database design, structure, and scope. Hum Mutat 2000;16:123-31.
14. Alter BP. Inherited bone marrow failure syndromes. CGB 2006. http://www.marrowfailure.cancer.gov
15. Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan M, Ling C, Rooimans MA, Bier P, Hoatlin M, Pals G, de Winter JP, Wang W, Joenje H. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 2004;36:1219-24.
16. Ikeda H, Matsushita M, Waisfisz Q, Kinoshita A, Oostra AB, Nieuwint AWM, de Winter JP, Hoatlin ME, Kawai Y, Sasaki MS, D'Andrea AD, Kawakami Y, Joenje H. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res 2003;63:2638-94.
17. Offit K, Levran O, Mullaney B, Mah K, Nafa K, Batish SD, Diotti R, Schneider H, Deffenbaugh A, Scholl T, Proud VK, Robson M, Norton L, Ellis N, Hanenberg H, Auerbach AD. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003;95:1548-51.
18. Alter BP, Tenner MS. Brain tumors in patients with Fanconi's Anemia. Arch Pediatr Adolesc Med 1994;148:661-3.
19. Hirsch B, Shimamura A, Moreau L, Baldinger S, Hag-Alshiekh M, Bostrom B, Sencer S, D'Andrea AD. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 2004;103:2554-9.
20. Wagner JE, Tolar J, Levran O, Scholl T, Deffenbaugh A, Satagopan J, Ben Porat L, Mah K, Batish SD, Kutler DI, MacMillan ML, Hanenberg H, Auerbach AD. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia and Fanconi anemia. Blood 2004;103:3226-9.
21. MacMillan ML, Auerbach AD, Wagner JE. Risk of malignancy in patients with biallelic BRCA2 mutations. Pediatr Blood Cancer 2005;44:539-40.
22. Reid S, Renwick A, Seal S, Baskcomb L, Barfoot R, Jayatilake H, Pritchard-Jones K, Stratton MR, Ridolfi-Luthy A, Rahman N. Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J Med Genet 2005;42:147-51.
23. Meyer S, Fergusson WD, Oostra AB, Medhurst AL, Waisfisz Q, de Winter JP, Chen F, Carr TF, Clayton-Smith J, Clancy T, Green M, Barber L, Eden OB, Will AM, Joenje H, Taylor GM. A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations. Genes Chromosomes Cancer 2005;42:404-15.
24. Faivre L, Portnoi MF, Pals G, Stoppa-Lyonnet D, le Merrer M, Thauvin-Robinet C, Huet F, Mathew CG, Joenje H, Verloes A, Baumann C. Should chromosome breakage studies be performed in patients with VACTERL association? Am J Med Genet A 2005;137:55-8.
25. Alter BP. The association between FANCD1/BRCA2 mutations and leukemia. Br J Haematol 2006;133:446-8.
26. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003;101:822-6.
27. Pyne MT, Brothman AR, Ward B, Pruss D, Hendrickson BC, Scholl T. The BRCA2 genetic variant IVS7 + 2T→G is a mutation. J Hum Genet 2000;45:351-7.
28. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BA, Lenoir GM. A polymorphic stop codon in BRCA2. Nat Genet 1996;14:253-4.
29. Godthelp BC, Wiegant WW, Waisfisz Q, Medhurst AL, Arwert F, Joenje H, Zdzienicka MZ. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res 2000;594:39-48.
30. Cox DG, Hankinson SE, Hunter DJ. No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:1353-4.
31. Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005;65:417-26.
32. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciemikova S, Foretova L, Soucek P, King M-C. Spectrum of mutations in BRCA1, BRCA2, CHEK2 and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379-88.
33. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001;2:446-59.
34. Ludwig T, Fisher P, Ganesan S, Efstratiadis A. Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 2001;15:1188- 93.
35. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VL, Ashworth A. Tumorigenesis and a DNA repair defect in mice wild a truncating Brca2 mutation. Nat Genet 1997;17:423-30.
36. Esmer C, Sanchez S, Ramos S, Molina B, Frias S, Carnevale A. DEB test for Fanconi anemia detection in patients with atypical phenotypes. Am J Med Genet 2004;124A:35-9.
37. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer 2003;97:425-40.